Telormedix is a biopharmaceutical company founded in 2007, with a focus on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. The company's slogan, "Pioneering targeted immunity for cancer and autoimmune disease treatment through innovative biopharma solutions," reflects its dedication to innovative biopharma solutions. Telormedix secured a notable €6.16M Series B investment on 02 December 2013, with funding from ProQuest Investments and Aravis. Telormedix operates within the Biopharma, Biotechnology, Health Care, and Health and Wellness industries.
No recent news or press coverage available for Telormedix.